Becton Dickinson eyes $600m revenue

Becton Dickinson and Co, a United States-based medical technology company, is targeting a 17 percent growth in sales from China this year to about $600 million, its chairman said.

China is already the second-largest market for the company after the US, said Vincent Forlenza, chairman of Becton Dickinson.

Medical devices, especially the infusion business, is still the largest revenue earner in China, said Forlenza, adding that Becton Dickinson's presence in the sector can be traced back to 1906, when it built up the first facility in the US to manufacture needles and syringes.